2007 |
Dr. Georg Brauers |
Regulatory Aspects of Pharmacogenomics in Clinical Drug Development *** |
|
|
2007 |
Jörg Cselovszky |
The New Regulatory Framework for Health Claims in the Eurpean Union Impact on the Demarcation of Food to Medicinal Products? *** |
|
|
2007 |
Claudia Fischer |
Investigational Medicinal Product Dossier (IMPD): CHMP/QWP/185401/2004-Guideline (Note for Guidance on the Requirements to the Chemical and Pharmaceutical Quality Documentation concerning Investigational Medicinal Products in Clinical trials): Comparison of requirements described in this guideline and in additional national guidance documents from exemplary EU countries and the emerging country India. Discussion of the impact on the compilation of a global IMPD for a multi-centre study |
|
|
2007 |
Ellen Frey-Stanislawski |
Revision of the Variation Regulations Commission Regulation (EC) No. 1084/2003 and No. 1085/2003 - Industry-Proposals and Consultation Paper from the European Commission, Impact on Industry and Health Authorities *** |
|
|
2007 |
Dr. Ulrich Fritsche |
An Overview of the Regulatory Framework of Fixed Dose Combination Medicinal Products (FDC) |
|
|
2007 |
Lena Gebert |
Impfstoffe für den Menschen - Ein Leitfaden über die besonderen arzneimittelrechtlichen Regelungen aus dem Arzneimittelgesetz *** |
|
|
2007 |
Anneke Hackling |
Clinical Trials in China |
|
|
2007 |
Yuwei Heinzel |
Regulatory Impact of the Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use (EMEA/CHMP/SWP/4447/00) on the Pharmaceutical Development |
|
|
2007 |
Elvira Holder |
Comparison of the requirements for simplified registration and marketing authorization procedure of homeopathic products with Austria, France, Germany, Italy and Switzerland |
|
|
2007 |
Wiebke Hoppensack |
Triggers for Regulatory Changes Implication of the TGN1412 incident on regulatory requirements for first-in-man trials *** |
|
|
2007 |
Dr. Frank Jeblonski |
New developments in European registration procedures and requirements, in particular consideration of biological/biotechnological-derived medicinal products |
|
|
2007 |
Dr. Anita Jörg |
Medicinal products during pregnancy and lactation an issue of risk management *** |
|
|
2007 |
Anja Karstens |
Differences between EU and US registration requirements for sterile human and veterinary products (quality part) for: a) First filing b) CMC changes |
|
|
2007 |
Dr. Bianca Krafft |
Scientific Advice - Value Adding Strategies for Regulatory Agencies and Pharmaceutical Companies *** |
|
|
2007 |
Michaela Krause |
ICH Q8 Pharmaceutical Development, ICH Q9 Quality Risk Management, ICH Q10 Pharmaceutical Quality System: vision, concept and their potential impact on industry and regulators will they foster innovation? *** |
|
|
2007 |
Ruth Lätzel |
Development of the ASEAN Pharmaceutical Harmonisation scheme - An Example of Regional Integration *** |
|
|
2007 |
Kirsten Martin |
Readability User Testing of package leaflets: Regulatory requirements, methodologies and assessment *** |
|
|
2007 |
Tünde Molnár |
Generics Medicines in the Centralised Procedure |
|
|
2007 |
Dr. Katrin Neubert |
Development of a rationale for deriving acceptance criteria for the validation of analytical methods in the pharmaceutical quality control |
|
|
2007 |
Angelika Ommeln |
Regulatory Data Analysis for the development of a database for country specific requirements *** |
|
|